What is Centrillion Biosciences?
Centrillion Biosciences operates at the intersection of high-throughput genomics and clinical diagnostics. By leveraging advanced DNA chip technology, the company provides critical tools for pathogen detection, including its specialized VirusHunter assays designed for SARS-CoV-2 variant tracking. Beyond infectious disease monitoring, the firm is a key player in whole genome genotyping and spatial transcriptomics, offering research institutions and clinical laboratories the precision required for complex biological analysis. Their platform is engineered to deliver cost-effective, high-accuracy results, effectively bridging the gap between laboratory research and public health implementation.
How much funding has Centrillion Biosciences raised?
Centrillion Biosciences has raised a total of $1M across 2 funding rounds:
Debt
$350K
Debt
$666K
Debt (2020): $350K with participation from PPP
Debt (2021): $666K led by PPP
Key Investors in Centrillion Biosciences
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Centrillion Biosciences?
With the recent influx of capital, Centrillion Biosciences is well-positioned to accelerate its enterprise-level expansion. The strategic focus will likely shift toward increasing manufacturing capacity for its diagnostic assays and broadening the commercial reach of its spatial transcriptomics suite. As the company navigates the post-pandemic diagnostic environment, the integration of its high-throughput sequencing capabilities into standard clinical workflows remains a primary objective. Investors are closely monitoring how this financing will facilitate the transition from specialized research applications to widespread, routine clinical adoption, potentially setting a new benchmark for efficiency in genomic surveillance and personalized medicine.
See full Centrillion Biosciences company page
